Purpose: Assessing the effectiveness of Bortezomib in multiple myeloma patients on clinical, clinical (rate of complete response, partial response or not, survive rate, time and recurrence rate). Method: Cohortstudy. Results: From 12/2006 to 12/2007, we treated 17 patients with multiple myeloma including: 06 patients with 8 cycles (35.29%), 01 patients with 6 cycles: (5.88%): 03 patients with 5 cycles (17.65%), 02 patients with 3 cycles (11.76%), 04 patients with 2 cycles (23.53%), and 01 patient with 1 cycle (5.88%).